Immuron (IMRN) EBT Margin (2016 - 2024)
Immuron (IMRN) posted quarterly EBT Margin of 20861482146754.5% for Q4 2024, up 2086148214684252.2% year-over-year from N/an in Q1 2024, and up 23703124045770.85% quarter-over-quarter from 88.01% in Q4 2023.
Immuron (IMRN) EBT Margin (2016 - 2024) Analysis & Trends
Immuron's EBT Margin history runs 9 years deep, the most recent figure standing at 20861482146754.5% for Q4 2024.
- In Q4 2024, EBT Margin rose 2086148214684252.2% year-over-year to 20861482146754.5%; the TTM figure through Dec 2024 stood at 15119849782968.0% (up 1511984978296831.0% YoY), while the FY2025 annual figure was 71.6%, up 6989.0% from the prior year.
- EBT Margin for Q4 2024 stood at 20861482146754.5%, up from 88.01% in the prior quarter.
- The five-year high for EBT Margin was 20861482146754.5% in Q4 2024, with the low at 390896616.51% in Q4 2020.
- The 5-year median for EBT Margin is 213.49% (2023), against an average of 3476848541369.59%.
- The sharpest annual moves came in 2020 and 2024: EBT Margin sank 2000000000 bps in 2020, then surged 2000000000 bps in 2024.
- Immuron's EBT Margin stood at 390896616.51% in 2020, then surged by 100 bps to 0.0% in 2021, then sank by 43219211 bps to 338.97% in 2022, then soared by 74 bps to 88.01% in 2023, then surged by 2000000000 bps to 20861482146754.5% in 2024.
- Business Quant data shows IMRN's EBT Margin at 20861482146754.5% in Q4 2024, 88.01% in Q4 2023, and 1493.47% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Immuron | 6.64 Mn | 6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20,861,482,146,754.51% |
| Dec 31, 2023 | -88.01% |
| Jun 30, 2023 | -1,493.47% |
| Dec 31, 2022 | -338.97% |
| Dec 31, 2021 | 0.00% |
| Dec 31, 2020 | -390,896,616.51% |
| Dec 31, 2019 | -97.73% |
| Dec 31, 2018 | -161.71% |
| Dec 31, 2017 | -202.76% |
| Dec 31, 2016 | -490.79% |
| Jun 30, 2016 | -379.89% |